Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. ALGS "Aligos"))), a clinical stage…#alg097558 #aligos #eposter #escmid #barcelona #spain #alg097558phase1 #nirmatrelvir #lawrenceblatt #phd
Source: Reuters: Health - Category: Consumer Health News Source Type: news